Trade Cogent Biosciences, Inc. - COGT CFD

Trade Cogent Biosciences, Inc. - COGT CFD

About Cogent Biosciences Inc

Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases. The Company's most advanced program is CGT9486, a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation, as well as other mutations in KIT exon 17, to treat Systemic Mastocytosis (SM) and gastrointestinal stromal tumors (GIST). GT9486 has demonstrated clinical activity and safety results in a Phase I/II clinical trial in patients with GIST, supporting accelerated timelines to proof-of-concept in SM.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Cogent Biosciences Inc revenues decreased from $7.9M to $0K. Net loss applicable to common stockholders decreased 60% to $72.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Acquired in-process research and develop decrease from $46.9M (expense) to $0K, Other income increase from $779K to $2.5M (income).